{
    "Clinical Trial ID": "NCT01031446",
    "Intervention": [
        "INTERVENTION 1: ",
        "  RAD001 and Cisplatin and Paclitazel",
        "  Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically confirmed invasive mammary carcinoma",
        "  Stage IV disease",
        "  Basal-like disease (triple-negative, hormone-refractory, HER2-negative)",
        "  No locally recurrent breast cancer",
        "  No symptomatic brain metastases",
        "  Patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers",
        "  Patients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers",
        "  PATIENT CHARACTERISTICS:",
        "  Pre- or post-menopausal",
        "  European Cooperative Oncology Group (ECOG) performance status 0-1",
        "  Life expectancy  6 months",
        "  Absolute neutrophil count (ANC)  1,000/mm^3",
        "  Platelet count  100,000/mm^3",
        "  Creatinine  1.5 times upper limit of normal (ULN)",
        "  Total bilirubin  1.5 times ULN ( 3 times ULN in the presence of liver metastasis)",
        "  Direct bilirubin will be measured in patients with Gilbert syndrome",
        "  serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT)  1.5 times ULN ( 3 times ULN in the presence of liver metastasis)",
        "  Alkaline phosphatase  3 times ULN (in the presence of liver metastasis)",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment",
        "  Able to swallow and retain oral medication",
        "  No malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel",
        "  No concurrent uncontrolled illness including, but not limited to, any of the following:",
        "  Ongoing or active infection requiring parenteral antibiotics",
        "  Impaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)",
        "  New York Heart Association class III-IV congestive heart failure",
        "  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months",
        "  Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)",
        "  Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0])",
        "  Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)",
        "  Psychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary",
        "  No symptomatic neuropathy  grade 2",
        "  No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ",
        "  No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies",
        "  No history of hepatitis B or C",
        "  PRIOR CONCURRENT THERAPY:",
        "  See Disease Characteristics",
        "  Recovered from prior therapy",
        "  Prior total cumulative life-time dose of doxorubicin  360 mg/m^2 or epirubicin  640 mg/m^2",
        "  No more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)",
        "  At least 2 weeks since prior investigational drugs",
        "  At least 14 days since prior and no concurrent herbal or dietary supplements",
        "  At least 14 days since prior and no concurrent CYP3A4 inducers",
        "  At least 7 days since prior and no concurrent CYP3A4 inhibitors",
        "  Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry",
        "  No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, immunotherapy, hormonal therapy, biologic therapy)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Maximum Feasible Dose in Milligrams Per Meter Squared of Body Surface Area (mg/m2) of Cisplatin and Paclitaxel for Women With Metastatic Breast Cancer",
        "  The recommended dose for the Phase II trial will be the most prevalent dose delivered per week in Phase I that allows for safe and feasible administration of the medications.The maximum tolerated dose (MTD) is defined as the dose preceding that at which 2 or more of 3 patients experience dose-limiting toxicity (DLT) during the initial cycle of therapy. DLTs include Common Toxicity Criteria (CTC) Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 x 10 9/L for > 5 days), febrile neutropenia (ANC < 1.0 x 10 0/L with fever > 38.5 degrees Centigrade) or documented infection associated with Grade 3-4 neutropenia, CTC Grade 4 thrombocytopenia < 25 x 10 9/L or CTC Grade 3 < 50-25 x 10 9/L thrombocytopenia with bleeding, and Grade 3-4 non-hematologic toxicity despite symptomatic therapy.",
        "  Time frame: at 8 weeks",
        "Results 1: ",
        "  Arm/Group Title: RAD001 and Cisplatin and Paclitazel",
        "  Arm/Group Description: Cisplatin intravenously (IV) weekly for 3 weeks, then 1 week of rest; paclitaxel IV weekly for 3 weeks, then 1 week of rest. Everolimus (RAD001) po daily. One cycle = 4 weeks",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Number",
        "  Unit of Measure: mg/m2  Cisplatin: 25",
        "Paclitaxel: 80"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 9/55 (16.36%)",
        "  neutrophils2/55 (3.64%)",
        "  leukocytes1/55 (1.82%)",
        "  platelets1/55 (1.82%)",
        "  febrile neutropenia, ANC < 1.0 x 10e9L, fever  38.5 degrees Celsius1/55 (1.82%)",
        "  anemia2/55 (3.64%)",
        "  thrombocytopenia2/55 (3.64%)",
        "  ventricular tachycardia1/55 (1.82%)",
        "  pain-abdomen3/55 (5.45%)",
        "  diarrhea1/55 (1.82%)",
        "  nausea3/55 (5.45%)",
        "  vomiting3/55 (5.45%)"
    ]
}